Journal of Frailty, Sarcopenia and Falls

Editorial

Sarcopenia and Hip Fractures

Yannis Dionyssiotis[1] and Andrea Olascoaga-Gómez de León[2]

[1]2nd Physical Medicine and Rehabilitation Department, National Rehabilitation Center EKA, Athens, Greece; [2]National Institute of Rehabilitation, Mexico City, Mexico

The global prevalence of sarcopenia is estimated to be between 7.5% and 77.6%. The prevalence largely varies according to the study characteristics ranging between 14 -33% in care facilities, 26% in spinal cord injuries and up to 78% in hospitalized patients with disability[1].

Approaches to defining sarcopenia remain controversial. The definition most cited today is that proposed by the European Working Group on Sarcopenia in Older People (EWGSOP), that has been updated in EWGSOP II in 2019. The EWGSOP II uses criteria to categorize each identified case as possible sarcopenia, established sarcopenia and severe sarcopenia based on: the presence of low muscle strength (criterion 1), low muscle mass (quality and quantity) (criterion 2), and low physical performance (criterion 3). The presence of criterion 1 identifies possible sarcopenia, criteria 1 and 2 confirm the diagnosis and if all 3 criteria are met sarcopenia is considered severe. This categorization is endorsed by several international scientific societies for clinical practice and research[2].

Many studies in the current literature present associations between revised definitions of sarcopenia and health complications such as functional decline, frailty, impaired quality of life, increased health care costs and mortality. Especially older adults suffering from sarcopenia are more than three times more likely to fall, regardless of age, sex, or comorbidities. Therefore, patients with hip fracture (especially older adults) are more likely to be sarcopenic[3,4]. Hip fracture is considered the most devastating among the fragility fractures, due to its unfavourable outcomes: reduced life expectancy with 8-36% increased mortality rate and reduced ability to function with approximately 10-20% of hip fracture survivors requiring long-term nursing home care, and only 40-70% fully regaining their preinjury level of independence[5].

When the decline of muscle mass and function following a hip fracture is not regained during recovery, the risk for recurrence of fall-related fractures will rise. Recent studies have shown an increased risk of a hip fracture of 40–60% with decrease in either muscle mass quantity (muscle cross-sectional area) or muscle quality (X-ray attenuation, echo intensity)[8,9].

Based on the current guidelines' sarcopenia diagnosis requires measurement of muscle strength, muscle mass, and physical performance[10], which may not be always feasible in hip fracture patients as mobility problems and pain limit this kind of assessment.

Within the EWGSOP II algorithm, the assessment of sarcopenia starts with a simple questionnaire for screening: SARC-F. In this questionnaire scoring ≥ 4 (to 10) can suggest sarcopenia[11]. However, this is not the case in hip fractured patients because these subjects are unable to perform some of the mobility tests, at least in the early rehabilitation phase of the hip fracture. Tests such as walking and climbing stairs are not possible due to difficulties in walking and balance. Diagnosis needs techniques such as handgrip strength, i.e. using a dynamometer, which is a validated and widely used method for measuring grip strength. Alternatively, without a measuring device strength could be assessed simply by measuring hand's fist, which is a subjective measurement because using this approach we are facing the problem of threshold, and the dependency of the test from motivation and possibility of pain for example due to osteoarthritis in hand. We also may face certain difficulties if the patient has cognitive impairment and may not be able to comply. However, measuring muscle strength is important because it defines possible sarcopenia (criterion 1 according to EWGSOP II). Other tests frequently used to assess muscle strength or physical performance (power) are Chair stands test (for criterion 1 in EWGSOP II), Walk test and Time up and Go test (for criterion 3,); again, these tests are not useful during the acute phase of hip fracture in the hospital.

The measurement of appendicular muscle mass through whole body composition analysis with dual energy x-ray

The authors have no conflict of interest.

Corresponding author: *Yannis Dionyssiotis, Head Director, 2nd Physical Medicine and Rehabilitation Department, National Rehabilitation Center EKA, Ilion, 13122, Athens, Greece*

E-mail: *yannis_dionyssiotis@hotmail.com*

Accepted *22 January 2024*

absorptiometry (DXA) is the clinical gold standard to define sarcopenia The skeletal muscle index (SMI), a ratio from appendicular skeletal muscle mass (ASM) divided by height^2 is a valuable number to establish the thresholds of the disease[11]. The problem lies here in the lack of whole body DXA software in many hospitals, making a body composition assessment in a hip fractured subject almost impossible, at least in the early stages. Although new techniques are emerging for measuring muscle quality and quantity, such as musculoskeletal ultrasound, there is a lack of cut-off points for different populations, which means these methods are still under constant investigation, but are not yet ready for use in a clinical context.

One study using DXA body composition after hip fracture found a 9% decrease in lower extremity lean mass and 5% in total body, from 10 days to 4 months, and another one a 6% decrease in total body from 10 days to 2 months, respectively[12-14]. A follow-up study found no significant change between 3 and 10 days in total body lean mass[15]. These results may create a timeline of intervention no later than 10 days for at least 2 months during rehabilitation phase[16].

Notably, reduced measures of muscle mass may worsen the prognosis following hip fracture. The prognosis in men compared to women after a hip fracture is poorer. In men, lean mass declines at a higher rate before and after a hip fracture and this may partially explain higher post-fracture mortality rate in men[6,7]. The prognostic value of malnutrition in rehabilitation settings is also established, and is associated with functional decline, especially protein-energy malnutrition, worse functional status and poor recovery[17]. Absence of malnutrition and high muscle strength were significantly associated with higher odds of functional recovery after hip fracture. On the other side there was no association between high skeletal lean mass and function[18].

A report from the International Sarcopenia Initiative (EWGSOP and IWGS) concluded that essential amino acids, including 2,5gr of leucine, β-hydroxy β-methylbutyrate (HMB) and the increase of protein intake to 1,2 gr/kg/day, could improve the muscle parameters[19]. Furthermore, older people not only need more protein than young adults, but also these nutrition interventions – need a suitable timetable and could be more beneficial with the inclusion of personalized exercise programs[20].

Currently, the diagnosis and management of sarcopenia in hip -fracture patients are extremely challenging, as there are no standardized diagnostic guidelines and treatment protocols. Despite this, possibilities are being explored. As research in hip-fracture patients keeps growing, heterogeneity in studies may diminish and this will lead to a better understanding regarding sarcopenia in this population. In addition, it will allow us to design targeted intervention strategies, starting from prevention.

References

1. Kyriakoulakou E, Manola M, Papathanasiou J, Groumas N, Petropoulou K, Dionyssiotis Y. Sarcopenia: a narrative review. Acta Orthopaedica et Traumatologica Hellenica 2019;70(3):98-107
2. Dennison EM, Sayer AA, Cooper C. Epidemiology of sarcopenia and insight into possible therapeutic targets. Nat Rev Rheumatol 2017;13(6):340-347.
3. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019; 393(10191):2636-2646.
4. Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CGM, Maier AB. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2019;10(3):485-500.
5. Di Monaco M, Castiglioni C, Bardesono F, et al. Sarcopenia, osteoporosis and the burden of prevalent vertebral fractures: a cross-sectional study of 350 women with hip fracture. Eur J Phys Rehabil Med 2020;56:184-190.
6. Omsland TK, Emaus N, Tell GS, Magnus JH, Ahmed LA, Holvik K, et al. Mortality following the frst hip fracture in Norwegian women and men (1999–2008) A NOREPOS study. Bone 2014;63:81–86.
7. Chen Y-P, Wong P-K, Tsai M-J, Chang W-C, Hsieh T-S, Leu T-H, et al. The high prevalence of sarcopenia and its associated outcomes following hip surgery in Taiwanese geriatric patients with a hip fracture. J Formos Med Assoc 2020;119(12):1807–1816
8. Inoue T, Maeda K, Nagano A, Shimizu A, Ueshima J, Murotani K, Sato K, Tsubaki A. Undernutrition, Sarcopenia, and Frailty in Fragility Hip Fracture: Advanced Strategies for Improving Clinical Outcomes. Nutrients 2020;12(12):3743.
9. Kramer IF, Blokhuis TJ, Verdijk LB, et al. Perioperative nutritional supplementation and skeletal muscle mass in older hip-fracture patients. Nutr Rev 2019;77(4):254-266
10. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 2020; 26(Suppl 1):1-46.
11. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al ; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48(1):16-31.
12. Karlsson M, Nilsson J, Sernbo I, Redlund-Johnell I, Johnell O, Obrant K. Changes of bone mineral mass and soft tissue composition after hip fracture. Bone 1996;18(1):19–22.
13. Fox K, Magaziner J, Hawkes W, Yu-Yahiro J, Hebel J, Zimmerman S, et al. Loss of bone density and lean body mass after hip fracture. Osteoporos Int 2000;11:31–35.
14. Reider L, Owen EC, Dreyer HC, Fitton LS, Willey MC; and METRC (Major Extremity Trauma Research Consortium). Loss of Muscle Mass and Strength After Hip Fracture: an Intervention Target for Nutrition Supplementation. Curr Osteoporos Rep 2023;21(6):710-718.
15. D'Adamo CR, Hawkes WG, Miller RR, Jones M, Hochberg M, Yu-Yahiro J, et al. Short-term changes in body composition after surgical repair of hip fracture. Age Ageing 2014;43(2):275–280.
16. Kouw IW, Groen BB, Smeets JS, Kramer IF, van Kranenburg JM, Nilwik R, et al. One week of hospitalization following elective hip surgery induces substantial muscle atrophy in older patients. J Am Med Dir Assoc 2019;20(1):35–42.
17. Dionyssiotis Y, Chhetri JK, Piotrowicz K, Gueye T, Sanchez E. Impact of nutrition for rehabilitation of older patients : report on the 1st EICA-ESPRM-EUGMS train the trainers course. Eur Geriatr Med

2017;8:183–190.
18. Irisawa H, Mizushima T. Relationship between nutritional status, body composition, muscle strength, and functional recovery in patients with proximal femur fracture. Nutrients 2022;14(11):2298.
19. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43(6):748-759.
20. Calvani R, Miccheli A, Landi F, et al. Current nutritional recommendations, and novel dietary strategies to manage sarcopenia. J Frailty Aging 2013;2(1):38-53.